Pink Sheet Podcast: Sharpless On Zolgensma, US FDA Leadership Changes And Appropriations
Our take on acting US FDA Commissioner Norman Sharpless' thoughts on press coverage of the Zolgensma approval, the agency's chief of staff announcing her departure, and the House Appropriations Committee approving the FDA's fiscal year 2020 funding bill.
You may also be interested in...
Virtual kick-off meetings may be necessary, but preparations continue in anticipation of the formal talks to reauthorize the prescription drug, generic drug and biosimilar user fee programs.
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
Likelihood of webcast-only advisory committee meetings may depend on the extent of the coronavirus outbreak, Office of New Drugs Director Peter Stein tells the Pink Sheet in an interview.